Stock ORGS ORGENESIS INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Orgenesis Inc.

Equities

ORGS

US68619K2042

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
0.5 USD -1.40% Intraday chart for Orgenesis Inc. -1.42% -0.14%
Apr. 16 North American Morning Briefing : Powell Comments, -2- DJ
Apr. 15 Orgenesis Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
North American Morning Briefing : Powell Comments, -2-
DJ
Orgenesis Provides Year End Business Update
AQ
Orgenesis Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Orgenesis : Non-Reliance on Previously Issued Financial Report - Form 8-K
PU
Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility
AQ
Germfree and Orgenesis Inc. Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility
CI
North American Morning Briefing : Stocks Seen -2-
DJ
North American Morning Briefing : Markets Steady -2-
DJ
North American Morning Briefing : Stock Futures -2-
DJ
Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference
AQ
Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes
AQ
Orgenesis Inc. announced that it has received $2.340901 million in funding
CI
Orgenesis Inc. Announces $2.3 Million Private Placement
AQ
Orgenesis Inc. announced that it expects to receive $2.340901 million in funding
CI
Orgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing
AQ
Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic
AQ
Orgenesis Inc. agreed to acquire 25% stake in Octomera LLC from MM OS Holdings, L.P.
CI
Orgenesis Inc. entered into a binding Term Sheet agreement to acquire Octomera LLC from MM OS Holdings, L.P.
CI
Alimera Sciences Appoints New CFO
MT
Orgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TM
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ORGS Stock
  4. News Orgenesis Inc.